# The Effect of Acipimox on GLP (Glucagon-like Peptide)-1 Secretion

> **NCT02796950** · NA · COMPLETED · sponsor: **University of Aarhus** · enrollment: 8 (actual)

## Conditions studied

- Diabetes Mellitus Type 2

## Interventions

- **DRUG:** Acipimox

## Key facts

- **NCT ID:** NCT02796950
- **Lead sponsor:** University of Aarhus
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2017-01-20
- **Final completion:** 2017-01-20
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2018-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02796950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02796950, "The Effect of Acipimox on GLP (Glucagon-like Peptide)-1 Secretion". Retrieved via MORVS 2026-10-23 from https://api.morvs.ai/clinical/NCT02796950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*